JAB-BX610
/ Jacobio Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2026
JAB-BX610, a First-in-Class Tissue Factor-Directed Antibody Drug Conjugate Delivering a Novel KRAS G12D Inhibitor
(EORTC-NCI-AACR 2026)
- "Abstract will be available as of 4 November (with consent of the author)"
ADC • Oncology • KRAS
1 to 1
Of
1
Go to page
1